27.04.2018
Medios AG DE000A1MMCC8
DGAP-News: Medios AG continues on its growth course after a successful financial year 2017
DGAP-News: Medios AG / Key word(s): Final Results/Forecast
Medios AG continues on its growth course after a successful financial year
2017
27.04.2018 / 11:53
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Corporate News
Medios AG continues on its growth course after a successful financial year
2017
* Specialty Pharma company publishes its Annual Report 2017
* Further significant sales and earnings increase in financial year 2017
* Managing Board confirms positive outlook for financial year 2018
Berlin, 27 April 2018 - Medios AG ("Medios"), one of the leading Specialty
Pharma companies in Germany, has published its Annual Report 2017 and
expects to continue on its dynamic growth course in financial year 2018
after a sharp increase in sales and earnings in 2017.
In financial year 2017, Group sales rose year on year by 58 per cent to EUR
254 million (IFRS; previous year EUR 160.4 million, pro-forma* IFRS).
Thereby, the Wholesale and Manufacturing segments generated sales of EUR 211
million and EUR 43 million respectively (IFRS). Group earnings before taxes
(EBT)** climbed by 38 per cent to EUR 8.0 million (IFRS; previous year EUR
5.8 million, pro-forma* IFRS), not including the share options for Group
employees** granted in 2017. The figures published in the Annual Report 2017
are largely the same as the preliminary figures for 2017 which had already
been published in January 2018.
Manfred Schneider, CEO of Medios AG: "In 2017, we continued to profit from
strong demand for individualised medicine and new regulatory approval of
innovative, high-priced therapies. But expanding our product range and our
network of partners also paid off. The positive outlook for the Specialty
Pharma market and the progress we have made in implementing our strategy
rapidly give us confidence that we will continue on our growth course in the
current financial year."
In 2017, Medios strengthened its successful strategic partnership with
Cranach Pharma and thereby laid the foundation for further synergies in the
Speciality Pharma business. Moreover, Medios started the announced expansion
of manufacturing capacities for individualised medicine at short notice
after the acquisition of additional clean-room capacities. Previously,
Medios had successfully issued new shares to institutional investors. The
total proceeds of some EUR 15.3 million from the capital increase will be
used to finance further growth.
For financial year 2018, the Managing Board still expects that the Medios
Group will continue to grow. Both operating segments - Wholesale and
Manufacturing - are expected to contribute to the growth. As part of the
growth strategy, further investments in personnel, technology and software
are planned.
Overall, Medios continues to expect an increase in Group sales of 26 per
cent to around EUR 320 million in financial year 2018 (IFRS). EBT is
intended to improve by 37 per cent to around EUR 11 million (IFRS) as
planned, not including the share options for Group employees granted in
2017.
The Annual Report 2017 for Medios AG was published today and is available
for downloading from the company website
http://medios.ag/en/investor-relations/financial-reports/.
* Non-recurring factors mean that the IFRS figures for 2017 are only
partially comparable with the IFRS figures for 2016. For an adequate
presentation of the Group's performance, Medios compares the IFRS figures
for 2017 with the pro-forma figures for 2016. Further explanations can be
found in the Annual Report 2017, Group Management Report, II. 3.
** EBT is defined as net earnings before income taxes.
*** The share options result in the recognition of additional staff expenses
of EUR 1.26 million in the consolidated financial statements for 2017. They
were granted at the Annual General Meeting in August 2017 by creating
contingent capital (Share Option Plan 2017), so do not represent a financial
expense for the Medios Group. Further explanations can be found in the
Annual Report 2017, Group Management Report, II. 3.1.1 and Group Notes, 34.
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As
wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of
patient-specific medications, Medios covers substantial elements of the
supply chain in this field and follows the highest international quality
standards. Specialty Pharma drugs are, in particular, individualised
infusions for patients with rare or chronic diseases like cancer, HIV and
hepatitis. It is Medios' aim to provide integrated solutions along the value
chain to partners and clients, thereby ensuring an optimal pharmaceutical
care for patients.
Medios AG is Germany's first listed Specialty Pharma company. The share
(WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the
Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock
Exchange.
Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Telephone: +49 40 60918618
Fax: +49 40 60918660
E-mail: [email protected]
www.kirchhoff.de
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the
forward-looking statements contained in this notification.
---------------------------------------------------------------------------
27.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: 030 / 8321 8377
E-mail: [email protected]
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of News DGAP News Service
---------------------------------------------------------------------------
679961 27.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Medios AG ISIN: DE000A1MMCC8 können Sie bei EQS abrufen
Gesundheit , A1MMCC , ILM1 , XETR:ILM1